{"id":"177lu-psma-617","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Xerostomia (dry mouth)"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Renal toxicity"}]},"_chembl":{"chemblId":"CHEMBL4594406","moleculeType":"Protein","molecularWeight":"1216.07"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This drug combines a lutetium-177 radioisotope with a small molecule ligand (617) that specifically targets PSMA, a cell-surface antigen highly expressed on prostate cancer cells. Once bound to PSMA, the radioisotope delivers localized beta radiation directly to tumor cells, causing DNA damage and cell death while minimizing exposure to healthy tissues. This approach is known as radioligand therapy or targeted radionuclide therapy.","oneSentence":"177Lu-PSMA-617 is a radioligand that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation therapy to kill PSMA-expressing tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:56:14.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"}]},"trialDetails":[{"nctId":"NCT04663997","phase":"PHASE2","title":"177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2021-08-11","conditions":"Prostate Cancer","enrollment":200},{"nctId":"NCT06526299","phase":"PHASE2","title":"Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-04-29","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":51},{"nctId":"NCT06780670","phase":"PHASE2, PHASE3","title":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-27","conditions":"Prostate Cancer","enrollment":443},{"nctId":"NCT06798558","phase":"PHASE2","title":"Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2025-03-05","conditions":"Prostate Adenocarcinoma","enrollment":54},{"nctId":"NCT04689828","phase":"PHASE3","title":"177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-15","conditions":"Prostatic Neoplasms","enrollment":469},{"nctId":"NCT07145177","phase":"PHASE1","title":"177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-16","conditions":"Metastatic Prostate Cancer, Prostate Cancer","enrollment":30},{"nctId":"NCT05658003","phase":"PHASE2","title":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-05","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT07477756","phase":"","title":"A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-09-04","conditions":"Prostate Cancer","enrollment":1247},{"nctId":"NCT05435495","phase":"","title":"Mechanisms of Resistance to PSMA Radioligand Therapy","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2021-10-21","conditions":"Prostate Cancer","enrollment":125},{"nctId":"NCT05114746","phase":"PHASE2","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-01-25","conditions":"Prostate Cancer","enrollment":87},{"nctId":"NCT06288113","phase":"PHASE2","title":"Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":40},{"nctId":"NCT06388369","phase":"PHASE1, PHASE2","title":"Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer","status":"TERMINATED","sponsor":"University Hospital, Essen","startDate":"2025-08-25","conditions":"Very High Risk Prostate Carcinoma","enrollment":1},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT04720157","phase":"PHASE3","title":"An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-09","conditions":"Prostatic Neoplasms","enrollment":1145},{"nctId":"NCT06216249","phase":"PHASE2","title":"Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-08-01","conditions":"Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":90},{"nctId":"NCT06004661","phase":"PHASE2","title":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-04","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":20},{"nctId":"NCT07450157","phase":"","title":"A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-06-23","conditions":"Prostate Cancer","enrollment":6448},{"nctId":"NCT05849298","phase":"PHASE2","title":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-03","conditions":"Prostatic Neoplasm","enrollment":49},{"nctId":"NCT07047118","phase":"PHASE2","title":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-03","conditions":"Prostatic Cancer, Castration-Resistant","enrollment":130},{"nctId":"NCT04443062","phase":"PHASE2","title":"Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-07-20","conditions":"Prostate Cancer","enrollment":58},{"nctId":"NCT06959433","phase":"PHASE3","title":"Lu-177 PSMA Treatment in Cell Renal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Ankara University","startDate":"2026-05-01","conditions":"Metastatic Renal Cancer","enrollment":20},{"nctId":"NCT06964958","phase":"PHASE2","title":"177LuPSMA in Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2025-07-31","conditions":"Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer","enrollment":24},{"nctId":"NCT06855277","phase":"PHASE3","title":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-07-01","conditions":"Prostate Cancer","enrollment":940},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT07226986","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-12-05","conditions":"PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy","enrollment":123},{"nctId":"NCT05670106","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-05-16","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":62},{"nctId":"NCT06700057","phase":"","title":"Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-11-01","conditions":"Prostate Cancer, Metastasis","enrollment":50},{"nctId":"NCT07219147","phase":"PHASE1","title":"177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-05","conditions":"Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT06866938","phase":"PHASE2","title":"Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-04-11","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":58},{"nctId":"NCT06531499","phase":"PHASE1","title":"A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-11","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":106},{"nctId":"NCT05766371","phase":"PHASE2","title":"Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-12-15","conditions":"Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":48},{"nctId":"NCT07150715","phase":"PHASE2","title":"Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-12-12","conditions":"Oligometastatic Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma","enrollment":107},{"nctId":"NCT05162573","phase":"PHASE1","title":"EBRT + Lu-PSMA for N1M0 Prostate Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2021-12-20","conditions":"Prostatic Neoplasm","enrollment":14},{"nctId":"NCT06568562","phase":"PHASE2","title":"XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-12-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":32},{"nctId":"NCT07054346","phase":"PHASE1","title":"Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617","status":"RECRUITING","sponsor":"Thomas Hope","startDate":"2025-07-08","conditions":"Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer","enrollment":45},{"nctId":"NCT06574880","phase":"PHASE1, PHASE2","title":"STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Angela Y. Jia, MD PhD","startDate":"2025-05-13","conditions":"Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer","enrollment":45},{"nctId":"NCT07025512","phase":"PHASE2","title":"177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-12-03","conditions":"Metastatic Castration Resistant Prostate Cancer, Cytopenia, Anemia","enrollment":40},{"nctId":"NCT06785636","phase":"PHASE1, PHASE2","title":"Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617","status":"RECRUITING","sponsor":"Pathos AI, Inc.","startDate":"2025-02-07","conditions":"mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Neoplasms, Male, Urogenital Neoplasms","enrollment":252},{"nctId":"NCT05079698","phase":"PHASE1","title":"A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-01","conditions":"Prostate Cancer","enrollment":27},{"nctId":"NCT07223034","phase":"PHASE1","title":"A Study of 177Lu-PSMA-617 in People With Gliomas","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-27","conditions":"Glioma, Diffuse Astrocytoma, IDH-Wildtype (Grade 2-4), Glioblastoma, IDH-wildtype","enrollment":20},{"nctId":"NCT05613894","phase":"PHASE1","title":"Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-07-14","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":33},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT06852820","phase":"PHASE2","title":"68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Melissa Lumish","startDate":"2025-09-22","conditions":"Liver Cancer, Hepatocellular Carcinoma, Metastatic Liver Cancer","enrollment":10},{"nctId":"NCT05113537","phase":"PHASE1, PHASE2","title":"Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Vadim S Koshkin","startDate":"2022-07-08","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":30},{"nctId":"NCT03042468","phase":"PHASE1, PHASE2","title":"Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2016-12","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06200103","phase":"PHASE2","title":"Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-05-03","conditions":"Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":236},{"nctId":"NCT06943495","phase":"PHASE1","title":"Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)","status":"RECRUITING","sponsor":"Jean-Mathieu Beauregard","startDate":"2025-08-15","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":60},{"nctId":"NCT05633160","phase":"PHASE1, PHASE2","title":"64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)","status":"TERMINATED","sponsor":"Clarity Pharmaceuticals Ltd","startDate":"2023-06-15","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":4},{"nctId":"NCT06738303","phase":"PHASE2","title":"Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-07-14","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":44},{"nctId":"NCT07096999","phase":"","title":"SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2025-01-23","conditions":"Metastatic Castration-Resistant Prostate Carcinoma","enrollment":60},{"nctId":"NCT05547386","phase":"PHASE3","title":"68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-05-09","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":163},{"nctId":"NCT04343885","phase":"PHASE2","title":"In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-04-21","conditions":"Metastatic Hormone Naive Prostate Cancer","enrollment":130},{"nctId":"NCT05560659","phase":"PHASE2","title":"Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy","status":"RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2023-12-14","conditions":"Oligometastatic Prostate Cancer","enrollment":92},{"nctId":"NCT06858995","phase":"","title":"Experience of 177Lu-PSMA-617-administration on Port Reservoir (TIVAP)","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2025-06-05","conditions":"Administration of Therapy","enrollment":107},{"nctId":"NCT06303713","phase":"PHASE1","title":"LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-05-22","conditions":"Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":37},{"nctId":"NCT06972628","phase":"PHASE2","title":"Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617","status":"RECRUITING","sponsor":"Ebrahim S Delpassand","startDate":"2025-05-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Prostate Cancer Patients With Bone Metastasis, Prostate Cancer (CRPC)","enrollment":30},{"nctId":"NCT03874884","phase":"PHASE1","title":"177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2019-07-09","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":70},{"nctId":"NCT05398302","phase":"PHASE1","title":"Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-04-26","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8","enrollment":30},{"nctId":"NCT05803941","phase":"PHASE4","title":"Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-08-14","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT05340374","phase":"PHASE1, PHASE2","title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2022-07-14","conditions":"Metastatic Castration-resistant Prostate Cancer, mCRPC","enrollment":35},{"nctId":"NCT05208229","phase":"","title":"The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2021-02-01","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":2},{"nctId":"NCT04597411","phase":"PHASE1","title":"Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer","status":"RECRUITING","sponsor":"Endocyte","startDate":"2021-04-01","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":99},{"nctId":"NCT06389097","phase":"","title":"SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-02-03","conditions":"Prostate Cancer, Advanced Cancer","enrollment":80},{"nctId":"NCT06461689","phase":"","title":"Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-12-31","conditions":"Prostate Cancer Metastatic","enrollment":80},{"nctId":"NCT03805594","phase":"PHASE1","title":"177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2019-05-10","conditions":"Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma","enrollment":43},{"nctId":"NCT06783348","phase":"PHASE2","title":"Radiopharmaceutical Treatment of Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-10-30","conditions":"Metastatic Clear Cell Renal Cell Carcinoma","enrollment":48},{"nctId":"NCT03511664","phase":"PHASE3","title":"Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Endocyte","startDate":"2018-05-29","conditions":"Prostate Cancer","enrollment":861},{"nctId":"NCT03454750","phase":"PHASE2","title":"Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2022-10-25","conditions":"Metastatic Castration Resistant Prostate Cancer, 68Ga-PSMA PET/CT Positive","enrollment":143},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT06706921","phase":"PHASE4","title":"18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"VA Greater Los Angeles Healthcare System","startDate":"2024-12-15","conditions":"Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Metastatic Prostate Cancer","enrollment":15},{"nctId":"NCT04430192","phase":"PHASE1, PHASE2","title":"Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2020-08-06","conditions":"Prostatic Neoplasms","enrollment":20},{"nctId":"NCT06329830","phase":"PHASE1, PHASE2","title":"177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2024-10","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT06546527","phase":"EARLY_PHASE1","title":"Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-08-01","conditions":"Prostate Cancer","enrollment":12},{"nctId":"NCT04419402","phase":"PHASE2","title":"Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2020-08-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":162},{"nctId":"NCT05150236","phase":"PHASE2","title":"EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC","status":"UNKNOWN","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2022-04-29","conditions":"Prostatic Neoplasms, Genital Neoplasms, Male, Urogenital Neoplasms","enrollment":93},{"nctId":"NCT06136377","phase":"NA","title":"Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.","status":"NOT_YET_RECRUITING","sponsor":"Centre Georges Francois Leclerc","startDate":"2024-01-31","conditions":"Patients With Metastatic Castration-resistant Prostate Cancer","enrollment":35},{"nctId":"NCT05613842","phase":"PHASE2","title":"Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP)","status":"COMPLETED","sponsor":"St Vincent's Hospital, Sydney","startDate":"2022-08-09","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT03658447","phase":"PHASE1, PHASE2","title":"PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2019-07-12","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":37},{"nctId":"NCT04825652","phase":"","title":"177Lu-PSMA-617 Managed Access Program for mCRPC Patients","status":"NO_LONGER_AVAILABLE","sponsor":"Advanced Accelerator Applications","startDate":"","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC)","enrollment":""},{"nctId":"NCT03392428","phase":"PHASE2","title":"A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2018-01-29","conditions":"Cancer of the Prostate, Metastatic Cancer","enrollment":201},{"nctId":"NCT03780075","phase":"PHASE1","title":"Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2018-04-15","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT05170555","phase":"NA","title":"Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2021-12-01","conditions":"Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT03545165","phase":"PHASE1, PHASE2","title":"177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2018-04-18","conditions":"Prostate Cancer","enrollment":6},{"nctId":"NCT03042312","phase":"PHASE2","title":"Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy","status":"TERMINATED","sponsor":"Endocyte","startDate":"2017-07-12","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":71},{"nctId":"NCT04801264","phase":"EARLY_PHASE1","title":"Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2020-09-01","conditions":"Adenoid Cystic Carcinoma","enrollment":40},{"nctId":"NCT03828838","phase":"PHASE1, PHASE2","title":"Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2018-07-01","conditions":"Prostate Neoplasm","enrollment":10},{"nctId":"NCT03403595","phase":"PHASE1","title":"177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-12-01","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":1,"reaction":"CYTOPENIA"},{"count":1,"reaction":"DIVERTICULITIS"},{"count":1,"reaction":"ERECTILE DYSFUNCTION"},{"count":1,"reaction":"INTESTINAL PERFORATION"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":158,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["177Lutetium -PSMA 617 also referred to as 177Lu-PSMA","Lutetium-177-PSMA-617","(177Lu)-PSMA-617","177Lu-PSMA","[177Lu]Lu-PSMA-617"],"phase":"phase_3","status":"active","brandName":"177Lu-PSMA-617","genericName":"177Lu-PSMA-617","companyName":"European Organisation for Research and Treatment of Cancer - EORTC","companyId":"european-organisation-for-research-and-treatment-of-cancer-eortc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"177Lu-PSMA-617 is a radioligand that binds to prostate-specific membrane antigen (PSMA) on cancer cells and delivers targeted radiation therapy to kill PSMA-expressing tumors. Used for Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":9,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}